Jazz Poised To Hold Onto Strong Sleep Disorder Position
Executive Summary
Jazz detailed Phase III data on a next-generation narcolepsy drug that could extend the life of its successful Xyrem franchise. The launch of Sunosi also is underway.
You may also be interested in...
Finance Watch: Coronavirus-Related Stock Market Meltdown Didn’t Stop Passage Bio IPO
Public Company Edition: The gene therapy firm’s IPO priced at $18 and ended its first day up 23.3% at $22.20 but fell to $21.50 when stocks recovered on 2 March. Also, RedHill raised $115m for product launches and Movantik purchase, and Avadel raised $65m to compete with Jazz.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Thumbs Up For Zulresso And Sunosi, Thumbs Down For Zynquista And IV Meloxicam
The latest drug development news and highlights from our US FDA Performance Tracker.